Finally, a recent study of 46 CLL cases identified PAX5 non‐coding mutations in 17.4% of CLL cases, which correlated with non‐coding elements of transcription elongation sites, and promoter and enhancer regions. This evidence concerns the gene PAX5 and B-cell chronic lymphocytic leukemia.